

Technical Information Report

AAMI TIR42: 2021

Evaluation of particulate
associated with vascular
medical devices

Evaluation of particulate associated with vascular medical devices

Approved 31 March 2021
by **AAMI**

Abstract: This document provides information for defining appropriate test methods, determining the source of particulate, assessing the clinical risk of particulate, and establishing product particulate limits. Particulate could arise from many sources including materials, environment, and clinical use. This TIR is intended to offer guidance to the medical device industry when evaluating the tendency for medical devices to release particulate, identifying particulate sources, applying analytical methods for particulate testing, and developing particulate limits based on clinical risk.

Keywords: acute, coating, emboli, hydrophilic, light microscopy, light obscuration, literature review, medical device, particle, particle counting, particulate limits, particulate matter, risk, simulated use, test method, validation

AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years but at least every 10 years. For a TIR, AAMI consults with a technical committee about five years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are voluntary, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 901 N. Glebe Road, Suite 300, Arlington, VA 22203.

Published by
AAMI
901 N. Glebe Road, Suite 300
Arlington, VA 22203
www.aami.org

© 2021 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, complete the reprint request form at www.aami.org or contact AAMI at 901 N. Glebe Road, Suite 300, Arlington, VA 22203. Phone: +1-703-525-4890; Fax: +1-703-276-0793.

Printed in the United States of America

ISBN 978-1-57020-787-7

This is a preview. [Click here to purchase the full publication.](#)

Contents

Page

Committee representation	iv
Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	1
3 Definitions	1
4 Introduction	2
5 Key characteristics for evaluation of particulate	2
6 Sources of particulate	3
7 Particulate evaluation test methods	7
8 Literature review	12
9 Considerations for establishing quantitative limits for product particulate	22
Annex A Summary of particulate characterization technologies	30
Bibliography	34

Tables

Table A.1—Primary particulate quantitation and sizing technologies	30
Table A.2—Additional particulate quantitation and sizing technologies	31
Table A.3—Particulate chemical identification technologies	32

Committee representation

Association for the Advancement of Medical Instrumentation

Medical Device Particulates Committee

This technical information report (TIR) was developed by the AAMI Medical Device Particulates Committee. Approval of the TIR does not necessarily imply that all committee members voted for its approval.

At the time this document was published, the **AAMI Medical Device Particulates Committee** had the following members:

<i>Cochairs:</i>	Terry Irwin, MBA, CMQ/OE Dinesh Patwardhan, PhD
<i>Project Leader:</i>	Eleni Whatley, PhD
<i>Members:</i>	Susanne Anderson, NAMSA August Baur, Centurion Sterilization Services Kendahl Bennis, Boston Scientific Martin Boehm, Shire/Takeda Pharmaceuticals Lindsey Borton, MPH, Smiths Medical Carolyn Braithwaite-Nelson, Spectranetics/Philips Alina Bridges, Mayo Clinic Amitabh Chopra, Camarillo, CA James Conti, PhD, Dynatek Labs Lydia Edgewater, W.L. Gore & Associates Paul Fioriti, B. Braun Medical Dan Floyd, CISS-EO, DuPont Tyvek Medical and Pharmaceutical Protection Doug Harbrecht, Sterility Assurance Ltd. Stephanie Hsia, Medtronic Neurovascular Yin Hu, MD, University Hospitals of Cleveland Terry Irwin, Edwards Lifesciences Allan Kimble, DuPuy Synthes USA/Johnson & Johnson Stan Lam, PhD, Stryker Neurovascular Rashi Mehta, West Virginia University Hospitals Rupal Mehta, Rush University Medical Center Tonya Morris, BS, Nelson Laboratories/Sotera Health Dinesh Patwardhan, U.S. Food and Drug Administration/CDRH Christin Pawleski-Hoell, Raumedic Inc. Sandi Schaible, WuXi Apptec Inc. Kyle Timme, Cook Research Craig Weinberg, PhD, Biomedical Device Consultants & Laboratories Neal Zupec, Baxter Healthcare Corporation
<i>Alternates:</i>	Brian Choules, PhD, Biomedical Device Consultants & Laboratories Robert John Evjen, Boston Scientific Siddharth Loganathan, Stryker Neurovascular Gerald McDonnell, PhD, Johnson & Johnson Nicholas Packet, DuPont Tyvek Medical and Pharmaceutical Protection Elaine Strobe, PhD, Dynatek Laboratories Carl Swanson, NAMSA Eleni Whatley, PhD, U.S. Food and Drug Administration/CDRH Preston Zook, Nelson Laboratories/Sotera Health

NOTE Participation by federal agency representatives in the development of this technical information report does not constitute endorsement by the federal government or any of its agencies.
